Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | -35.65% | -59.63% | -81.89% |
| EV / EBITDA | 0.00 | -3.27 | -4.20 | -0.86 |
| Quality | ||||
| ROIC | 0.00% | -18.42% | -18.42% | -18.76% |
| Gross Margin | 0.00% | -164.29% | -164.29% | -81.07% |
| Cash Conversion Ratio | 0.62 | 0.62 | 0.48 | -0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,078,921.18% | 1,046,677.73% | 1,014,518.59% | 869,678.43% |
| Free Cash Flow Growth | 0.00% | 0.00% | -20.21% | 47.31% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.89 | -1.63 | -0.07 |
| Interest Coverage | 0.00 | -10.14 | -171.95 | -61.16 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -25.69 | -25.69 | 4.08 |